Technical Analysis for XNCR - Xencor, Inc.

Grade Last Price % Change Price Change
grade D 33.21 3.49% 1.12
XNCR closed down 3.69 percent on Tuesday, February 25, 2020, on 2.4 times normal volume.

Trend Table & Recent Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Down Down Down
Historical XNCR trend table...

Date Alert Name Type % Chg
Lower Bollinger Band Walk Weakness 3.49%
Earnings Movers Other 3.49%
Outside Day Range Expansion 3.49%
Below Lower BB Weakness 3.49%
Down 3 Days in a Row Weakness 3.49%
Lower Bollinger Band Touch Weakness 3.49%
MACD Bearish Signal Line Cross Bearish -0.33%
Expansion Pivot Sell Setup Bearish Swing Setup -0.33%
Earnings Movers Other -0.33%
Gapped Down Weakness -0.33%

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile

Xencor, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing engineered monoclonal antibodies to treat severe and life-threatening diseases. It develops its antibody product candidates to treat autoimmune and allergic diseases, cancer, and other conditions through XmAb technology platform. The company's engineered antibodies that are in development include XmAb5871, a B-cell inhibitor that is in Phase Ib/IIa clinical trials for the treatment of autoimmune diseases, such as rheumatoid arthritis and lupus; XmAb7195, an IgE inhibitor to treat severe asthma and allergic diseases; and XmAb5574/MOR208, a Cytotoxic B-cell depleting product candidate for the treatment of B-cell cancers. It has a collaboration agreement with Boehringer Ingelheim International GmbH; and development and manufacturing services agreement with Catalent Pharma Solutions LLC. The company was founded in 1997 and is based in Monrovia, California.
Medicine Biotechnology Biopharmaceutical Cancer Medical Specialties Life Sciences Immunology Antibodies Autoimmune Diseases Immune System Monoclonal Antibodies Antibody Rheumatoid Arthritis Glycoproteins Treatment Of Autoimmune Diseases Lupus Boehringer Ingelheim Immunoglobulin E Manufacturing Services Agreement

Is XNCR a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 46.33
52 Week Low 27.75
Average Volume 288,680
200-Day Moving Average 36.92
50-Day Moving Average 36.06
20-Day Moving Average 35.22
10-Day Moving Average 35.42
Average True Range 1.56
ADX 15.34
+DI 12.01
-DI 27.02
Chandelier Exit (Long, 3 ATRs ) 32.59
Chandelier Exit (Short, 3 ATRs ) 36.37
Upper Bollinger Band 37.92
Lower Bollinger Band 32.53
Percent B (%b) -0.08
BandWidth 15.32
MACD Line -0.49
MACD Signal Line -0.19
MACD Histogram -0.3066
Fundamentals Value
Market Cap 1.51 Billion
Num Shares 46.9 Million
EPS -0.87
Price-to-Earnings (P/E) Ratio -36.89
Price-to-Sales 29.06
Price-to-Book 3.08
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 36.28
Resistance 3 (R3) 36.61 35.55 35.58
Resistance 2 (R2) 35.55 34.48 35.38 35.34
Resistance 1 (R1) 33.82 33.83 33.29 33.49 35.11
Pivot Point 32.76 32.76 32.50 32.59 32.76
Support 1 (S1) 31.03 31.69 30.50 30.70 29.07
Support 2 (S2) 29.97 31.04 29.80 28.84
Support 3 (S3) 28.24 29.97 28.60
Support 4 (S4) 27.91